Holen Sie sich die Stockscreener-App
26.44
3.36%
0.86
Handel nachbörslich:
26.44
Schlusskurs vom Vortag:
$25.58
Offen:
$25.8
24-Stunden-Volumen:
151.91K
Relative Volume:
0.69
Marktkapitalisierung:
$367.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.38M
KGV:
-5.0464
EPS:
-5.2394
Netto-Cashflow:
$-51.00M
1W Leistung:
+0.46%
1M Leistung:
-8.07%
6M Leistung:
+83.23%
1J Leistung:
+349.66%
1-Tages-Spanne:
$25.57
$26.78
1-Wochen-Bereich:
$23.13
$28.03
52-Wochen-Spanne:
$4.90
$35.62
Forte Biosciences Inc Stock (FBRX) Company Profile
Firmenname
Forte Biosciences Inc
Sektor
Branche
Telefon
(310) 618-6994
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
26.44 | 355.20M | 0 | -69.38M | -51.00M | -5.2394 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-18 | Eingeleitet | Guggenheim | Buy |
| 2025-01-21 | Eingeleitet | TD Cowen | Buy |
| 2024-04-08 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Hochstufung | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Herabstufung | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Herabstufung | Truist | Buy → Hold |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-26 | Eingeleitet | Citigroup | Buy |
| 2020-08-28 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Eingeleitet | Truist | Buy |
Alle ansehen
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
Tech Rally: Is Forte Biosciences Inc trading at a discount2026 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Published on: 2026-04-05 11:22:35 - baoquankhu1.vn
Precision Trading with Forte Biosciences Inc. (FBRX) Risk Zones - Stock Traders Daily
Forte Biosciences and Pasithea Therapeutics Face Off in Financial Comparison - National Today
Forte Biosciences (NASDAQ: FBRX) CFO exercises RSUs, 134 shares withheld - stocktitan.net
Forte Biosciences (FBRX) director boosts stake after RSU vesting - stocktitan.net
Guggenheim reiterates Forte Biosciences stock rating ahead of data By Investing.com - Investing.com India
Guggenheim reiterates Forte Biosciences stock rating ahead of data - Investing.com
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - marketbeat.com
Forte Biosciences Reports 2025 Financial Results and Provides FB102 Clinical Development Updates for Celiac Disease, Vitiligo, and Alopecia Areata - Minichart
FB102 trials drive higher 2025 R&D at Forte Biosciences (NASDAQ: FBRX) - stocktitan.net
Forte Biosciences (NASDAQ:FBRX) Announces Quarterly Earnings Results - marketbeat.com
Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Forte Biosciences (NASDAQ: FBRX) advances FB102 with positive celiac data and funds trials through equity raises - Stock Titan
Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Forte Biosciences, Inc. Announces 2025 Results and Provides Update - The Joplin Globe
Three FB102 disease readouts are due in 2026 after Forte spent $58M - stocktitan.net
Reviewing Pasithea Therapeutics (NASDAQ:KTTA) and Forte Biosciences (NASDAQ:FBRX) - Defense World
FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences, Inc.: Fundamental Analysis and Financial Ratings | | US34962G2084 - MarketScreener
Technical Reactions to FBRX Trends in Macro Strategies - Stock Traders Daily
Rally Mode: Is Forte Biosciences Inc a top pick in the sectorEarnings Miss & Growth Oriented Trade Recommendations - baoquankhu1.vn
Forte Biosciences Inc expected to post a loss of $1.21 a shareEarnings Preview - tradingview.com
Pullback Watch: Will Forte Biosciences Inc announce a stock splitQuarterly Performance Summary & High Win Rate Trade Tips - baoquankhu1.vn
If You Invested $1,000 in Forte Biosciences Inc (FBRX) - Stock Titan
Forte Biosciences (FBRX) Projected to Post Earnings on Friday - marketbeat.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - MarketBeat
Aug Fed Impact: Does Forte Biosciences Inc have pricing power2026 Price Targets & Growth Focused Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - The Joplin Globe
Mink Brook Asset Management LLC Buys 42,419 Shares of Forte Biosciences, Inc. $FBRX - MarketBeat
New hires at Forte Biosciences get options on 25,000 shares - stocktitan.net
Trading the Move, Not the Narrative: (FBRX) Edition - Stock Traders Daily
History Review: Can Forte Biosciences Inc maintain its current growth rateGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
FBRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FBRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Bank Watch: Can LOKV lead its sector in growth2025 Support & Resistance & Momentum Based Trading Ideas - baoquankhu1.vn
Can Forte Biosciences Inc. stock beat analyst upgradesEarnings Beat & Growth Focused Stock Pick Reports - Naître et grandir
Can Forte Biosciences Inc. stock maintain growth trajectoryWeekly Loss Report & Technical Confirmation Alerts - Naître et grandir
Portfolio Update: Can MKTW withstand a market correction2025 Analyst Calls & Community Verified Trade Alerts - baoquankhu1.vn
Forte Biosciences (FBRX) Price Target Increased by 16.98% to 53.30 - MSN
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules - marketscreener.com
Vitiligo Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Stock Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Biotech Forte Biosciences hands 100,000 stock options to new hires - Stock Titan
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
(FBRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBRX PE Ratio & Valuation, Is FBRX Overvalued - Intellectia AI
Forte Biosciences (FBRX) Raised to Buy: Key Information You Need - Bitget
Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Forte Biosciences Inc-Aktie (FBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):